Phase II study of neoadjuvant S-1 concurrent radiotherapy for borderline resectable pancreatic cancer

Trial Profile

Phase II study of neoadjuvant S-1 concurrent radiotherapy for borderline resectable pancreatic cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 A randomized controlled trial comparing neoadjuvant CRT and chemotherapy, including gemcitabine+nab-paclitaxel, for borderline resectable pancreatic cancer is under planning as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 28 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top